Pear Therapeutics eyes short extension of exclusive plan periods

By Sarah Lizee

Olympia, Wash., April 30 – Pear Therapeutics, Inc. is seeking a seven-day extension of its exclusive periods to file and solicit votes on a Chapter 11 plan, according to a motion filed Tuesday with the U.S. Bankruptcy Court for the District of Delaware.

The company asked the court to extend the exclusive plan filing period through May 13 from May 6 and the exclusive solicitation period through July 8 from July 1.

The company filed a plan and disclosure statement on March 4. The plan confirmation hearing is set for May 7.

Pear said the extension is warranted since the plan hearing is one day after the exclusive filing period expires.

“Allowing the expiration of the exclusive periods at this stage could interfere with the substantial progress that the debtors have made in the months following the petition date,” the company said in the motion.

Boston-based Pear Therapeutics develops and commercializes software-based medicines called prescription digital therapeutics. The company filed bankruptcy on April 7, 2023 under Chapter 11 case number 23-10429.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.